Article Details
Retrieved on: 2024-01-22 23:26:20
Tags for this article:
Click the tags to see associated articles and topics
Summary
ArriVent Biopharma, aiming to treat non-small-cell lung cancer targeting EGFR mutations, increased its IPO goal to $150M, advancing its drug candidate furnmonertinib in Phase 3 trials.
Article found on: seekingalpha.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here